CN113632988B - 一种益生菌包埋微囊的制备方法 - Google Patents
一种益生菌包埋微囊的制备方法 Download PDFInfo
- Publication number
- CN113632988B CN113632988B CN202110908349.5A CN202110908349A CN113632988B CN 113632988 B CN113632988 B CN 113632988B CN 202110908349 A CN202110908349 A CN 202110908349A CN 113632988 B CN113632988 B CN 113632988B
- Authority
- CN
- China
- Prior art keywords
- solution
- sodium alginate
- preparation
- microcapsule
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 66
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 66
- 239000003094 microcapsule Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000000661 sodium alginate Substances 0.000 claims abstract description 74
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 74
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 74
- 239000000243 solution Substances 0.000 claims abstract description 74
- 230000001580 bacterial effect Effects 0.000 claims abstract description 61
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 45
- 239000011521 glass Substances 0.000 claims abstract description 45
- 239000012982 microporous membrane Substances 0.000 claims abstract description 45
- 230000000529 probiotic effect Effects 0.000 claims abstract description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000011259 mixed solution Substances 0.000 claims abstract description 20
- 229920006221 acetate fiber Polymers 0.000 claims abstract description 19
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 18
- 238000007710 freezing Methods 0.000 claims abstract description 9
- 230000008014 freezing Effects 0.000 claims abstract description 9
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims description 28
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 20
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 239000010802 sludge Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 15
- 238000004090 dissolution Methods 0.000 claims description 14
- 239000001110 calcium chloride Substances 0.000 claims description 10
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000648 calcium alginate Substances 0.000 abstract description 2
- 235000010410 calcium alginate Nutrition 0.000 abstract description 2
- 229960002681 calcium alginate Drugs 0.000 abstract description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000009413 insulation Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种益生菌包埋微囊的制备方法,包括以下步骤:(1)菌泥制备;(2)海藻酸钠溶液制备;(3)氯化钙溶液制备;(4)微囊制备:将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于‑60~‑40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。本发明所制得的益生菌包埋微囊,囊壁材料是由化学反应形成的海藻酸钙醋酸纤维酞酸酯薄膜,具有隔水抗氧耐酸的优点,可以较好的保存益生菌的活性。
Description
技术领域
本发明属于食品工程领域,涉及一种益生菌包埋微囊的制备方法。
背景技术
治疗胃黏膜损伤的药物有质子泵抑制剂(奥美拉唑等)、抑酸剂(碳酸氢钠等)、胃黏膜保护剂(枸橼酸铋钾等)和抗幽门螺旋杆菌药物等等。大多数患者会选用化学药物治疗胃黏膜的损伤,然而化学药物除了有治疗疾病的作用外,一般还会刺激胃肠道,使原本受损的胃肠粘膜进一步受损,副作用大,长时间使用很容易破坏机体的平衡,使病情加重,还有可能引起其他疾病的产生。例如,服用奥美拉唑产生的不良反应有腹泻、头痛、恶心、胃肠胀气及便秘,有些病例中可发生胃黏膜细胞增生和萎缩性胃炎,服用超过8周会增加艰难梭菌感染及骨折的风险;枸橼酸铋钾也不宜长期服用,当血铋浓度超过0.1微克/毫升的时候,有可能导致铋性脑病,初期表现为慢性头痛、失眠、精神异常等,亦可突然发生明显的脑病症状,如精神错乱、肌肉强直、运动失调、构音障碍、幻觉、惊厥等;长期大量服用克拉霉素会引起肝肾损伤以及心律失常等严重不良反应。
益生菌是通过定殖在人体内,改变宿主某一部位菌群组成的一类对宿主有益的活性微生物。其功能是可以调节宿主黏膜与系统免疫功能,也可以调节肠道内菌群平衡,促进营养吸收保持肠道健康,从而产生有利于健康的作用。
由于药物的副作用和益生菌的保护肠道粘膜屏障的功能,越来越多肠胃亚健康的人群选择益生菌。
但由于益生菌是活的微生物,制剂质量与活菌数量密切相关,因此,如何使益生菌在加工过程、运输贮存过程和胃肠道耐受性等方面保证高活菌数量,对益生菌制剂的质量非常关键。益生菌对环境应激非常敏感,特别对水分活度、氧化还原作用、温度和酸等应激因子的影响最为明显,并且其不能耐受胃酸和胆盐,原料菌粉不经处理直接食用的话,经过胃肠道后绝大部分已经失活。
发明内容
本发明的目的是提供一种益生菌包埋微囊的制备方法。本发明与现有技术相比,本发明所述的益生菌包埋微囊的制备方法制备出来微囊,可以耐受胃酸和胆盐,使内部包裹的益生菌能够达到小肠,而不会出现到达小肠之前就大量失活的情况。
本发明采用以下技术方案实现上述目的:
一种益生菌包埋微囊的制备方法,包括以下步骤:
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
将3-5重量份聚乙二醇400,1-2重量份醋酸纤维酞酸酯,3-5重量份海藻酸钠,88-93重量份纯净水混合均匀配成溶液,用碳酸钠调pH值至7.8,灭菌得到海藻酸钠溶液;
(3)氯化钙溶液制备
将氯化钙、纯净水按照氯化钙3~5份、纯净水95~97份的重量比,混合均匀后将溶解升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比(1-4):(27-30)的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
其中,所述益生菌指的是青春双歧杆菌、动物双歧杆菌(乳双歧杆菌)、两歧双歧杆菌、短双歧杆菌、婴儿双歧杆菌、长双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德氏乳杆菌保加利亚亚种(保加利亚乳杆菌)、德氏乳杆菌乳亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌、嗜热链球菌中的一种或几种。
其中,海藻酸钠溶液制备步骤如下:
按以下比例进行备料:3-5重量份聚乙二醇400,1-2重量份醋酸纤维酞酸酯,3-5重量份海藻酸钠,88-93重量份纯净水;
将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液。
本发明所制得的益生菌包埋微囊,囊壁材料是由化学反应形成的海藻酸钙醋酸纤维酞酸酯薄膜,具有隔水抗氧耐酸的优点,可以较好的保存益生菌的活性。
具体实施方式
为了使本技术领域的人员更好地理解本发明方案,下面结合具体实施方式对本发明作进一步的详细说明。
原料说明
实施例1
按以下步骤制备益生菌微囊
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
海藻酸钠溶液:将聚乙二醇400、醋酸纤维酞酸酯、海藻酸钠、纯净水按照3:1:3:93重量比进行备料,将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液;
(3)氯化钙溶液制备
按照重量份数计,将氯化钙、纯净水按照3:97的重量比,混合均匀后将溶解升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比1:30的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
实施例2
按以下步骤制备益生菌微囊
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
海藻酸钠溶液:将聚乙二醇400、醋酸纤维酞酸酯、海藻酸钠、纯净水按照4:1.5:4:90.5重量比进行备料,将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液;
(3)氯化钙溶液制备
按照重量份数计,将氯化钙、纯净水按照4:96的重量比,混合均匀后将溶液升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比2:29的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
实施例3
按以下步骤制备益生菌微囊
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
海藻酸钠溶液:将聚乙二醇400、醋酸纤维酞酸酯、海藻酸钠、纯净水按照5:2:5:88重量比进行备料,将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液;
(3)氯化钙溶液制备
按照重量份数计,将氯化钙、纯净水按照5:95的重量比,混合均匀后将溶液升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比4:27的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
对比例1
按以下步骤制备益生菌微囊
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
海藻酸钠溶液:将聚乙二醇400、醋酸纤维酞酸酯、海藻酸钠、纯净水按照2:1:2:95重量比进行备料,将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液;
(3)氯化钙溶液制备
按照重量份数计,将氯化钙、纯净水按照2:98的重量比,混合均匀后将溶解升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比5:30的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
对比例2
按以下步骤制备益生菌微囊
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
海藻酸钠溶液:将聚乙二醇400、醋酸纤维酞酸酯、海藻酸钠、纯净水按照6:3:6:85重量比进行备料,将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液;
(3)氯化钙溶液制备
按照重量份数计,将氯化钙、纯净水按照6:94的重量比,混合均匀后将溶解升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比6:30的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
对比例3
按以下步骤制备益生菌微囊
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
海藻酸钠溶液:将聚乙二醇400、醋酸纤维酞酸酯、海藻酸钠、纯净水按照6:3:2:89重量比进行备料,将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液;
(3)氯化钙溶液制备
按照重量份数计,将氯化钙、纯净水按照7:93的重量比,混合均匀后将溶解升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比7:30的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊。
表1实施例和对比例的海藻酸钠溶液的原料重量比
实施例1 | 实施例2 | 实施例3 | 对比例1 | 对比例2 | 对比例3 | |
聚乙二醇400 | 3 | 4 | 5 | 2 | 6 | 6 |
醋酸纤维酞酸酯 | 1 | 1.5 | 2 | 1 | 3 | 3 |
海藻酸钠 | 3 | 4 | 5 | 2 | 6 | 2 |
纯净水 | 93 | 90.5 | 88 | 95 | 85 | 89 |
表2实施例和对比例的氯化钙溶液的原料重量比
实施例1 | 实施例2 | 实施例3 | 对比例1 | 对比例2 | 对比例3 | |
氯化钙 | 3 | 4 | 5 | 2 | 6 | 7 |
纯净水 | 97 | 96 | 95 | 98 | 94 | 93 |
表3菌泥与海藻酸钠溶液重量比
将实施例1-3和对比例1-3得到的益生菌包埋微囊,进行以下测试。
实验方法:取样品200袋(每袋不少于5g)于留样柜中,在室温条件下自然摆放24个月,分别在放置第0、3、6、9、12、18、24个月时取出20袋样品,按照以下方法检测样品中乳酸杆菌的活菌数量。
检测方法:将0.5g的L-cysteins HCL,4.5g的KH2PO4,6g的Na2HPO4,0.5mL的Tween80用蒸馏水适量溶解、定容,配成终体积为1000mL的溶液,再用0.1mol/L的NaOH溶液调节溶液的pH值至7.8,然后将此稀释液按每管9mL分装至试管中,再以灭菌釜用121℃灭菌15min,待用。其余试剂及培养基参照《GB 4789.35-2016食品安全国家标准食品微生物学检验乳酸菌检验》中的第4项进行配制。称取1g受试样品,加入已灭菌的稀释液试管中,于振荡器上震荡20min,使之混合溶解均匀,必要时离心弃去溶液中的沉淀物。将上述溶液按照比例连续稀释至适当的倍数。选择2个以上的适宜稀释度,按照《GB 4789.35-2016》中的第6项进行菌落培养并计数。
实验结果:见表4
表4益生菌微囊在室温摆放试验中的稳定性情况(益生菌活性单位:10亿CFU/g)
存放时间/月 | 0 | 3 | 6 | 9 | 12 | 18 | 24 |
实施例1 | 13.0 | 9.0 | 8.1 | 7.6 | 6.7 | 4.8 | 3.5 |
实施例2 | 12.1 | 8.5 | 7.3 | 7.1 | 6.4 | 4.1 | 2.8 |
实施例3 | 13.2 | 8.3 | 7.5 | 7.0 | 7.1 | 4.8 | 3.4 |
对比例1 | 12.8 | 5.6 | 3.7 | 3.3 | 1.7 | 0.9 | 0.5 |
对比例2 | 12.9 | 5.8 | 3.9 | 3.2 | 1.6 | 1.0 | 0.4 |
对比例3 | 13.1 | 4.3 | 2.8 | 1.9 | 1.2 | 0.6 | 0.2 |
结果分析:实施例1-3制作的益生菌微囊在室温放置2年后,益生菌活性明显高于对比例1-3。
以上所述实施例仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进,这些改进也应视为本发明的保护范围。
Claims (1)
1.一种益生菌包埋微囊的制备方法,其特征在于包括以下步骤:
(1)菌泥制备
将益生菌于液体MRS培养基上37℃条件下培养50小时,收集菌液并进行离心,收集菌体,用灭菌生理盐水洗涤3次,再次离心后制得菌泥;
(2)海藻酸钠溶液制备
将3-5重量份聚乙二醇400,1-2重量份醋酸纤维酞酸酯,3-5重量份海藻酸钠,88-93重量份纯净水混合均匀配成溶液,用碳酸钠调pH值至7.8,灭菌得到海藻酸钠溶液;
(3)氯化钙溶液制备
将氯化钙、纯净水按照氯化钙3~5份、纯净水95~97份的重量比,混合均匀后将溶解升温至90摄氏度灭菌,冷却后用稀盐酸调pH值至5,得氯化钙溶液;
(4)微囊制备
将菌泥与海藻酸钠溶液按照重量比(1-4):(27-30)的比例混合均匀,将菌泥和海藻酸纳溶液的混合液加入玻璃微孔膜过滤器内,玻璃微孔膜圆孔的直径为15微米,玻璃微孔膜上方的容器与氮气增压泵连通,玻璃微孔膜的下方浸在氯化钙溶液中,菌泥和海藻酸纳溶液的混合液在氮气增压泵的压力作用下通过玻璃微孔膜,进入到氯化钙溶液中,形成益生菌包埋微囊,收集益生菌微囊,于-60~-40℃下预冻1~5h,真空冷冻干燥后得到益生菌微囊;所述益生菌指的是青春双歧杆菌、动物双歧杆菌、两歧双歧杆菌、短双歧杆菌、婴儿双歧杆菌、长双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、德氏乳杆菌保加利亚亚种、德氏乳杆菌乳亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌、嗜热链球菌中的一种或几种;
海藻酸钠溶液制备步骤如下:
按以下比例进行备料:3-5重量份聚乙二醇400,1-2重量份醋酸纤维酞酸酯,3-5重量份海藻酸钠,88-93重量份纯净水;
将聚乙二醇400和纯净水配成溶液,然后加入醋酸纤维酞酸酯,完全溶解后加入海藻酸钠,升温至90摄氏度后均质,用碳酸钠调pH值至7.8,然后灭菌,得到海藻酸钠溶液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110908349.5A CN113632988B (zh) | 2021-08-09 | 2021-08-09 | 一种益生菌包埋微囊的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110908349.5A CN113632988B (zh) | 2021-08-09 | 2021-08-09 | 一种益生菌包埋微囊的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113632988A CN113632988A (zh) | 2021-11-12 |
CN113632988B true CN113632988B (zh) | 2023-09-08 |
Family
ID=78420205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110908349.5A Active CN113632988B (zh) | 2021-08-09 | 2021-08-09 | 一种益生菌包埋微囊的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113632988B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115363216B (zh) * | 2022-08-12 | 2023-07-04 | 昆明理工大学 | 一种利用发酵罐气升法制备益生菌微胶囊的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688221A (zh) * | 2012-04-27 | 2012-09-26 | 陕西科技大学 | 一种醋氯芬酸肠溶微囊的制备方法 |
CN104825503A (zh) * | 2015-04-24 | 2015-08-12 | 成都汇智远景科技有限公司 | 东革阿里提取物肠溶片 |
CN106418547A (zh) * | 2016-10-09 | 2017-02-22 | 西安创客村电子商务有限责任公司 | 一种益生菌微胶囊及其制备方法 |
CN106993813A (zh) * | 2017-03-31 | 2017-08-01 | 宝健(北京)生物技术有限公司 | 一种益生菌微胶囊的制备方法 |
WO2021136507A1 (zh) * | 2019-12-31 | 2021-07-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201712406A2 (tr) * | 2017-08-21 | 2019-03-21 | Nanomik Biyoteknoloji A S | Probiyotik Yüklü Mikrokapsüller Ve Bunların Üretimi |
-
2021
- 2021-08-09 CN CN202110908349.5A patent/CN113632988B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688221A (zh) * | 2012-04-27 | 2012-09-26 | 陕西科技大学 | 一种醋氯芬酸肠溶微囊的制备方法 |
CN104825503A (zh) * | 2015-04-24 | 2015-08-12 | 成都汇智远景科技有限公司 | 东革阿里提取物肠溶片 |
CN106418547A (zh) * | 2016-10-09 | 2017-02-22 | 西安创客村电子商务有限责任公司 | 一种益生菌微胶囊及其制备方法 |
CN106993813A (zh) * | 2017-03-31 | 2017-08-01 | 宝健(北京)生物技术有限公司 | 一种益生菌微胶囊的制备方法 |
WO2021136507A1 (zh) * | 2019-12-31 | 2021-07-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113632988A (zh) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Survival of Bifidobacterium longum immobilized in calcium alginate beads in simulated gastric juices and bile salt solution | |
CN113088465B (zh) | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 | |
WO2021114658A1 (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
CN108783462A (zh) | 一种肠道益生菌制剂的工业生产方法 | |
CN106399141A (zh) | 一种脆弱拟杆菌及其应用 | |
CN109156686B (zh) | 一种基于微囊化的提高发酵果汁贮藏期益生菌活性的方法 | |
CN111534435B (zh) | 一种可提高双歧杆菌耐酸性的冻干保护剂及其应用 | |
CN115141775B (zh) | 一种提升益生菌的自身功效及富硒能力的培养方法及其应用 | |
WO2022188335A1 (zh) | 基于壳聚糖-Fe包衣的能耐胃酸并肠道靶向释放的合生素微胶囊及其制备方法 | |
CN105733978B (zh) | 一株屎肠球菌wefa23 | |
CN113632988B (zh) | 一种益生菌包埋微囊的制备方法 | |
CN112890204A (zh) | 一种利用葡萄籽提取物作为益生元的微胶囊及其制备方法 | |
Jayalalitha et al. | In vitro assessment of microencapsulated probiotic beads. | |
CN111713685A (zh) | 一种微胶囊壁材及其在制备益生菌微胶囊中的应用 | |
US20240108047A1 (en) | Probiotic microcapsule and preparation method thereof | |
CN113424965A (zh) | 一种更适合黄种人群的微生态制剂 | |
CN117305189A (zh) | 一种德氏乳杆菌保加利亚亚种vb183及其培养装置和应用 | |
CN111264870A (zh) | 一种高环境抗性的益生菌微胶囊及其制备方法 | |
KR102004204B1 (ko) | 안정성이 증진된 유산균 및 이의 제조방법 | |
CN116570029A (zh) | 一种核桃低聚肽益生菌微胶囊及其制备方法 | |
CN105733977B (zh) | 益生菌饲料添加剂 | |
CN111529511B (zh) | 一种益生菌微胶囊及其制备方法与应用 | |
CN110591950B (zh) | 一株可以提高肠道il-22表达量的干酪乳杆菌 | |
CN114747769A (zh) | 一种益生菌制品及其制备方法 | |
CN110938563B (zh) | 一种乳酸菌bj-reborn001及其在制备抑制幽门螺旋杆菌的发酵液中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |